I

IX Biopharma Ltd
SGX:42C

Watchlist Manager
IX Biopharma Ltd
SGX:42C
Watchlist
Price: 0.11 SGD -1.79%
Market Cap: 105.2m SGD

Relative Value

The Relative Value of one 42C stock under the Base Case scenario is hidden SGD. Compared to the current market price of 0.11 SGD, IX Biopharma Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

42C Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
34
vs Industry
43
Median 3Y
5.6
Median 5Y
8.6
Industry
2.6
vs History
vs Industry
Median 3Y
-3.6
Median 5Y
-5.9
Industry
21.7
vs History
vs Industry
36
Median 3Y
-4.7
Median 5Y
-4.8
Industry
16.6
vs History
vs Industry
26
Median 3Y
-4
Median 5Y
-4.3
Industry
22.5
vs History
3
vs Industry
13
Median 3Y
4.8
Median 5Y
5.3
Industry
2.3
vs History
34
vs Industry
41
Median 3Y
5.1
Median 5Y
7.7
Industry
2.9
vs History
12
vs Industry
14
Median 3Y
17.1
Median 5Y
12.1
Industry
5.5
vs History
vs Industry
34
Median 3Y
-4
Median 5Y
-4.2
Industry
13.1
vs History
vs Industry
25
Median 3Y
-3.6
Median 5Y
-3.7
Industry
16.6
vs History
vs Industry
42
Median 3Y
-4.1
Median 5Y
-4.7
Industry
15.8
vs History
vs Industry
31
Median 3Y
-3.8
Median 5Y
-4.4
Industry
19.1
vs History
11
vs Industry
28
Median 3Y
3
Median 5Y
6.6
Industry
1.9

Multiples Across Competitors

42C Competitors Multiples
IX Biopharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SG
IX Biopharma Ltd
SGX:42C
97.7m SGD 12.6 -9.6 -18.9 -16.3
US
Eli Lilly and Co
NYSE:LLY
954.7B USD 16.1 51.9 34.8 37.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
505.3B USD 5.5 20.1 16.4 21.3
CH
Roche Holding AG
SIX:ROG
253.1B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.1 108.4 158.7
CH
Novartis AG
SIX:NOVN
203.4B CHF 4.6 17.8 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
246.3B USD 3.8 12.9 9.2 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 9.6 11.1
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
146.7B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
SG
I
IX Biopharma Ltd
SGX:42C
Average P/E: 23.5
Negative Multiple: -9.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.1
38%
0.8
CH
Novartis AG
SIX:NOVN
17.8
17%
1
US
Merck & Co Inc
NYSE:MRK
12.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SG
I
IX Biopharma Ltd
SGX:42C
Average EV/EBITDA: 437.6
Negative Multiple: -18.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.8
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SG
I
IX Biopharma Ltd
SGX:42C
Average EV/EBIT: 1 878.6
Negative Multiple: -16.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.3
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3